Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis

Biochemical Pharmacology

Volumn 76, Issue 4, 2008, Pages 453-462

  Vandenberghe, Isabelle ^a   Créancier, Laurent ^a   Vispé, Stéphane ^a   Annereau, Jean Philippe ^a   Barret, Jean Marc ^a   Pouny, Isabelle ^b   Samson, Arnaud ^a   Aussagues, Yannick ^a   Massiot, Georges ^b   Ausseil, Frédéric ^a   Bailly, Christian ^a   Kruczynski, Anna ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Apoptosis; Luciferase ubiquitin reporter; Natural compound; Physalin; Proteasome inhibitor; Ubiquitin proteasome pathway

Indexed keywords

BORTEZOMIB; CAMPTOTHECIN; EPOXOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; LUCIFERASE; PHYSALIN B; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN NOXA; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CATALYSIS; CELL ASSAY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; PLANT EXTRACTS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; SECOSTEROIDS; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 48149091924     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.05.031     Document Type: Article

References (34)

1. Goldberg A.L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35 (2007) 12-17
2. Hershko A., and Ciechanover A. The ubiquitin system. Annu Rev Biochem 67 (1998) 425-479
3. Kisselev A.F., Callard A., and Goldberg A.L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281 (2006) 8582-8590
4. Schwartz A.L., and Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 50 (1999) 57-74
5. Adams J. Potential for proteasome inhibition in the treatment of cancer. DDT 8 (2003) 307-315
6. Kane R.C., Bross P.F., Farell A.T., and Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncology 8 (2003) 508-513
7. Kisselev A.F., and Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8 (2001) 739-758
8. Dantuma N.P., Lindsten K., Glas R., Jellne M., and Masucci M.G. Short-lived fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 18 (2000) 538-543
9. Luker G.D., Pica C.M., Song J., Luker K.E., and Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat Med 9 (2003) 969-973
10. Stack J.H., Whitney M., Rodems S.M., and Pollok B.A. A ubiquitin-based tagging system for controlled modulation of protein stability. Nat Biotechnol 18 (2000) 1298-1302
11. Ausseil A., Samson A., Aussagues Y., Vandenberghe I., Créancier L., Pouny I., et al. High throughput bioluminescence screening of ubiquitin-proteasome pathway inhibitors from natural sources. J Biomol Screen 12 (2007) 106-116
12. Antoun M.D., Abramson D., Tyson R.L., Chang C.J., McLaughlin J.L., Peck G., et al. Potential antitumor agents. VII. Physalin B and 25,26 epidihydro physalin C from Whiteringia coccoloboides. J Nat Prod 44 (1981) 579-585
13. Kawai M., and Matsuurai T. Structure of physalin C: a bitter principle of Physalis alkekengi var francheti. Tetrahedron 26 (1970) 1743-1745
14. Maret A., Galy B., Arnaud E., Bayard F., and Prats H. Inhibition of fibroblast growth factor 2 expression by antisense RNA induced a loss of the transformed phenotype in a human hepatoma cell line. Cancer Res 55 (1995) 2075-2079
15. Vispe S., Vandenberghe I., Robin M., Boyer M., Annereau J.P., Créancier L., et al. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Biochem Pharmacol 73 (2007) 1863-1872
16. Wang E.W., Kessler B.M., Borodovsky A., Cravatt B.F., Bogyo M., Ploegh H.L., et al. Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity. Proc Natl Acad Sci USA 97 (2000) 9990-9995
17. Thrower J.S., Hoffman L., Rechsteiner M., and Pickart C.M. Recognition of the polyubiquitin proteolytic signal. EMBO J 19 (2000) 94-102
18. Zhu Q., Wani G., Wang Q., El-mahdy M., Snapka R.M., and Wani A.A. Deubiquitination by proteasome is coordinated with substrate translocation for proteolysis in vivo. Exp Cell Res 307 (2005) 436-451
19. Qin J.Z., Ziffra J., Stennett L., Bodner B., Bonish B.K., Chaturvedi V., et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65 (2005) 6282-6293
20. Tsukamoto S., and Yokosawa H. Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development. Curr Med Chem 13 (2006) 745-754
21. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer cell 8 (2005) 407-419
22. Sekizawa R., Ikeno S., Nakamura H., Naganawa H., Matsui S., Linuma H., et al. Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme. J Nat Prod 65 (2002) 1491-1493
23. Tsukamoto S., Hirota H., Imachi M., Fujimuro M., Onuki H., Ohta T., et al. Himeic acid A: a new ubiquitin-activating enzyme inhibitor isolated from a marine-derived fungus, Aspergillus sp. Bioorg Med Chem Lett 15 (2005) 191-194
24. Duncan S.J., Gruschow S., Williams D.H., McNicholas C., Purewal R., Hajek M., et al. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J Am Chem Soc 123 (2001) 554-560
25. Jocobo-Herera N.J., Bremner P., Márquez N., Gupta M.P., Gibbons S., Munoz E., et al. Physalins from Witheringia solanacea as modulators of the NF-κB cascade. J Nat Prod 69 (2006) 328-331
26. Tan X., Osmulski P.A., and Gaczynska M. Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design. Curr Med Chem 13 (2006) 155-165
27. Verma R., Peters N.R., D'Onofrio M., Tochtrop G.P., Sakamoto K.M., Varadan R., et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306 (2004) 117-120
28. Gomez-Bougie P., Wuillème-Toumie S., Ménoret E., Trichet V., Robillard N., Moreau P., et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67 (2007) 5418-5424
29. Fernández Y., Verhaegen M., Miller T.P., Rush J.L., Steiner P., Opipari A.W., et al. Differential regulation of NOXA in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic indications. Cancer Res (2005) 6294-6303
30. Kupchan S.M., Anderson W.K., Bollinger P., Doskotch R.W., and Smith R.M. Tumor inhibitors. XXXIX. Active principles of Acnistus arborescens. Isolation and structural and spectral studies of withaferin A and withacnistin. J Org Chem 34 (1969) 3858-3866
31. Minguzzi S., Barata L.E., Shin Y.G., Jonas P.F., Chai H.B., Park E.J., et al. Cytotoxic withanolides from Actinus arborescens. Phytochemistry 59 (2002) 635-641
32. Fang L., Chai H.B., Castillo J.J., Soejarto D.D., Farnsworth N.R., Cordell G.A., et al. Cytotoxic constituents of Brachistus stramoniifolius. Phytother Res 15 (2003) 520-523
33. Veras M.L., Bezerra M.Z.B., Braz-Filho R., Pessoa O.D.L., Montenegro R.C., Pessoa C., et al. Cytotoxic epimeric withaphysalins from leaves of Actinus arborescens (Solanacae). Planta Med 70 (2004) 551-555
34. Ferreira Magalhaes H.I., Veras M.L., Rocha Torres M., Negreiros Nunes Alves A.P., Pessoa O.D.L., Rocha Silveira E., et al. In vitro and in vivo antitumour activity of physalins B and D from Physalis angulata. J Pharm Pharmacol 58 (2006) 235-241